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Abstract
Background: Atrial fibrillation (AF) is an arrhythmia with complex pathophysiological cha-
racteristics. The efficiency of various anti-tachyarrhythmic stimulation algorithms in patients
with recurrent AF has become a subject of research and the aim of this analysis is to evaluate
the success of treatment by continuous DDD(R) stimulation with an anti-tachyarrhythmic
pacing algorithm in patients with paroxymal AF.
Methods: In the period 2002–2004 19 patients (10 females and 9 males), aged 45–74 (with
a mean age of 64.2 ± 7.6), qualified for DDD(R) system implantation. The indication for
implantation was tachy-brady syndrome with recurrent AF resistant to pharmacological treat-
ment. All the patients had had at least three recurrences of symptomatic AF within the previous
year. The follow-up period was 12 months. AF recurrences, outpatient visits and hospitalisa-
tion frequency were evaluated every 6 months and there were routine pacemaker controls.
Baseline and final visit echocardiograms and a quality of life (QoL) questionnaire (SF-36)
were obtained.
Results: One patient was excluded from the analysis owing to permanent AF with a final VVI
pacing mode. In comparison with the pre-inclusion 12 months AF-related hospitalisation
frequency within the 12-month follow-up period was 3.9 vs. 0.4 (p < 0.005) and outpatient
visits 2.1 vs. 0.8 (p < 0.05). The mean atrial pacing percentage in all patients was 95.7% ±
± 2.9%, and the mode switch percentage during the first and second 6 month periods was
6.4% (1–50%, median 2) and 2.5% (0–7, median 2, NS) respectively. There were 483/month
(0.44–5761, median 31) events defined as AF episodes during first 6 months and 84/month
(0–480, median 17, NS) during the second 6 months. The AF burden was 1.92 days/month
(7 h – 15 days, median 14 h), decreasing to 0.74 day/month (0–2.1 days, median 14 h, NS) in
the second 6-month period. A significant 12-month improvement was achieved in QoL parameters.
Conclusions: An overdrive atrial algorithm can be a beneficial, safe and comfortable method
in patients with paroxysmal drug-resistant AF and accepted indications for physiological
pacing. (Folia Cardiol. 2006; 13: 590–595)
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Introduction
Atrial fibrillation (AF) is the most common
tachyarrhythmia observed in humans [1, 2] and
morbidity increases in the elderly. AF is a recur-
rent supraventricular tachyarrhythmia and is fre-
quently resistant to numerous introduced drugs. Its
occurrence is associated with haemodynamic com-
promise and an increased risk of embolic events and
thus results in increased mortality, morbidity and
healthcare costs. One of the most important disad-
vantages of AF is a worsening of quality of life
(QoL). Two main strategies of treatment, namely
rhythm control and rate control, may be maintained
and their effectiveness remains the subject of nu-
merous trials. Both may provoke pharmocothera-
peutical side effects which result in restrictions on
drug use. As AF is a disease of complex origin, many
alternative and hybrid modes of treatment have
been considered [3–6] and permanent cardiac pac-
ing with anti-tachycardiac atrial pacing algorithms
is one of these, especially when AF is an element
of tachy-brady syndrome.
The aim of the present analysis was evaluation
of the permanent cardiac DDD(R) pacing mode with
an algorithm of anti-tachycardiac atrial pacing in
patients with tachy-brady syndrome and recurrent
drug-resistant atrial fibrillation.
Methods
In the period 2002–2004 DDD(R) pacemakers
were implanted in 19 patients (10 females and
9 males), aged 45–74 (with a mean age of 64.2 ± 7.6).
The study population characteristics are presented
in Table 1.
The indication for permanent pacing in all pa-
tients was tachy-brady syndrome with recurrent AF
resistant to pharmacotherapy. The occurrence of at
least three incidents of AF within the preceding
year constituted a further criterion for inclusion in
the study. The informed consent of all the patients was
obtained.
The exclusion criteria were unstable angina,
myocardial infarction within 3 months of the quali-
fying visit, heart failure assigned to NYHA classes
III and IV, post-surgical right atrium abnormalities,
artificial tricuspid heart valve, Wolff-Parkinson-
-White syndrome or AF with a reversible cause.
The study was designed as a prospective ob-
servation with a one year follow-up period. Every
6 months the following were evaluated:
— the frequency of recurrence of AF and the AF
burden stored in the pacemaker Holter memory;
— the number of hospitalisations and outpatient
visits following AF incidents;
— concomitant pharmacotherapy.
Each patient was asked to complete a quality
of life (QoL) questionnaire (SF-36) at baseline and
on the final visit. On the same visits M-mode and
two-dimensional echocardiograms were taken. The
protocol of the study was accepted by the local
Bioethics Committee.
Implantation procedure and
special functions of the pacemaker
The pacemaker implantation procedure was al-
ways performed while the patients remained in sinus
rhythm. If AF was diagnosed at admission, cardio-
version was undertaken. All patients were given an
Integrity AFxDR St. Jude Medical device, which was
equipped with an AF suppression algorithm, enabling
permanent right atrium overdrive. Atrial fibrillation
suppression (AFS) is one of the anti-tachyarrhyth-
mic features available among pacing products. Its
operation is based on permanent spontaneous sinus
activity detection. As soon as two consecutive atrial
beats are sensed, a smooth overdrive is provided for
the next 16 A-A intervals. Unless further atrial
activity occurs, the atrial rate is then decreased to
the basic programmed rate. Any atrial beats activate
the atrial overdrive once more (Fig. 1).
The auto mode switch (AMS) causes automatic
conversion from DDD(R) to DDI(R) mode if any atrial
tachycardia occurs at a rate above that programmed.
The atrial fibrillation suppression function is deacti-
vated during this time. When a leading rhythm is
Table 1. The basic demographic, clinical and medi-
cation characteristics of the study population.
Age (years) 64.2 ± 7.6
Female/male 10/9
Concomitant diseases
Arterial hypertension 14
Coronary artery disease 6
Diabetes 2
Medication
Beta-blocker 16
Sotalol 1
Propafenone 8
Amiodarone 3
Calcium blockers 4
Digoxin 2
ACE-inhibitor 16
Diuretics 6
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found outside the AMS window, the pacing mode is
restored to DDD(R). The pacemaker Holter memo-
ry provides data on mean heart rate, AMS frequen-
cy and the cumulative percentage of paced A-events
which may correspond to AF occurrence.
Statistics analysis
Statistical analysis was made by SAS 8.0e. Wil-
coxon score tests were used to compare continu-
ous variables, the distribution of which was not
Gaussian in the sample. Student’s t-test was used
for the comparison of two population means with
normal distribution.
Owing to differences in results, minimal and
maximal values were given and medians calculated.
Results
In one patient AF was diagnosed as permanent
after 1 month and the pacemaker was turned to VVIR
mode. In the remaining patients dual-chamber pacing
was sustained throughout the study period.
In the 12-month follow-up the frequency of AF
hospitalisation decreased from 3.9 to 0.4 (p < 0.005)
and outpatient visits due to AF decreased from
2.1 to 0.8 (p < 0.05) in comparison with the same
period before implantation. In the pacemakers’ Hol-
ter memory the A-pacing rate was 95.7 ± 2.9%,
which demonstrated an acceptable overdrive func-
tion. The mean AMS activity rate was 6.4% (1–50%,
median 2) during the first 6 months of observation,
decreasing to 2.5% (0–7, median 2, NS) in the next
6 months. Events recorded as tachycardia de-
creased between the two halves of the follow-up
period from a mean of 483 events/month (0.44–
–5761, median 31) to 84 events/month (0–480, me-
dian 17, NS). The AF burden was 1.92 days/month
(7 h – 15 days, median 14 h), decreasing to 0.74 day/
/month (0–2.1 days, median 14 h, NS) in the sec-
ond 6-month period.
Echocardiographic baseline and 12-month visit
parameters did not differ. These were, respective-
ly, left ventricle ejection fraction (EF) 42% (20–65,
median 45, NS) and 43% (22–60, median 43, NS) and
left atrium diameter 3.72 cm (2.5–5.4, median 3.5,
NS) and 3.93 cm (3.0–5.7, median 3.9, NS).
The SF-36 questionnaire demonstrated a re-
markable improvement in QoL in the population
studied. These results were achieved in a global
scale and, with the exception of the physical func-
tioning and bodily pain criteria, were comparable in
selected subgroups (Table 2).
During follow-up anti-arrhythmic drugs were
modified in 8 patients: in 3 patients propafenone,
calcium blocker and amiodarone were withdrawn,
in 3 patients amiodarone (1) and digoxin (2) were
added and in 2 patients propafenone and calcium
blocker were replaced by amiodarone.
Figure 1. Atrial fibrillation suppression algorithm. At the DDD mode (initially A-R), overdrive at 84 ppm. Two P-P
beats are detected (cycles 680 ms and 664 ms). Pacing rate is immediately accelerated to 93 ppm (A-A 648 ms) and
sustained by 16 consecutive beats. Unless atrial activity is detected meanwhile, the pacing rate decreases to the
basic programmed value.
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Discussion
The initial suggestion that cardiac pacing may
influence atrial tachyarrhythmias came from retro-
spective observations of patients treated with pace-
makers as a result of sick sinus syndrome. Subjects
implanted with physiological AAI or DDD systems
had fewer AF incidents than those with VVI pace-
makers [7–9]. This resulted in specially designed
trials to determine whether physiological pacing
demonstrates superiority over ventricular pacing
alone in reducing AF paroxysms [10–12]. In the
Canadian Trial of Physiologic Pacing [13], the Pace-
maker Selection in the Elderly Trial [14] and the
Mode Selection Trial [15] it was demonstrated that
DDD pacing decreased incidents of arrhythmia and
its conversion to permanent AF form. Physiologi-
cal cardiac pacing may have a bidirectional
haemodynamic and electrical effect. Sequential atrio-
ventricular pacing decreased mean pressure in the
atrial, reducing the strain and reverse remodelling.
Electrical physiological activity could 1) eliminate
or reduce brady-cardia-induced AF, 2) make acti-
vity homogenous to prevent atrial re-entry or
3) make refraction homogenous. In addition, the
atrial overdrive mechanism can provide premature
arrhythmogenic atrial beat suppression.
Our results may support the thesis that per-
manent atrial overdrive prevents AF incidents. As
in the CAP [16] and PROVE [17] trials, the atrial
pacing percentage was high, reaching a mean value
of 96%. This was followed by a decrease in AMS
activity from 6.4% in the first 6 months after pace-
maker implantation to 2.5% in the next 6 months. The
AF burden was reduced from 1.92 days/month to
0.74 days/month respectively. The ADOPT trial [18]
demonstrated that the AFS algorithm reduced the AF
burden by 25% compared to controls. The AF burden
in the AFS group was 3.19%, 1.93% and 1.37% after
1, 3, and 6 months respectively (by 60% compared to
the first month of observation). In the ADOPT trial
the first evaluation of the AFS mode was made after
1 month and the next after 3 months, when AF fre-
quency reduction was greatest, exceeding our obser-
vations (from 3.19% to 1.93%, by 40%). The next visit
took place 3 months later (in the 6th month) and the
reduction was not so remarkable (from 1.93% to
1.37%, by 29%) and corresponded to our results.
AF incident reduction also resulted in a de-
crease in hospitalisations and outpatient visits. In
our group reductions were achieved in hospitalisa-
tion and outpatient intervention of 90% and 62%
respectively at one-year follow-up. The decrease in
medical care interventions was probably related not
only to the reduction in the absolute AF burden but
also to amelioration of the characteristics of the AF
incidents, which were shorter, well tolerated and
often self-terminating. A common observation was
that an arrhythmia stored in the device’s Holter
memory had not been perceptible.
Table 2. Quality of life assesements.
SF-36 Parameter Baseline After p p
12 months  (Student’s (npar-
t-test)  -test)
Scale 1 Physical functioning 12.2 ± 10.6 8.1 ± 10.9  0.0724 (NS) 0.0986
0–40, median 12.5   0–40, median 5.0
Scale 2 Role limitations due 15.0 ± 7.3 (1.8) 9.7 ± 8.1 (2.0) 0.0097 0.0137
to physical problems  median 20  median 7.5
Scale 3 Social functioning 3.9 ± 2.3 (0.6) 2.4 ± 2.1 (0.5) 0.0256 0.0273
median 4  median 2.5
Scale 4 Bodily pain 3.5 ± 2.6 (0.7) 3.3 ± 2.3 (0.6) NS NS
median 3.5  median 3.5
Scale 5 General mental health 12.2 ± 4.7 (1.2) 8.1 ± 3.3 (0.8) 0.0024 0.0024
median 13  median 8
Scale 6 Role limitations due 7.5 ± 5.5 3.6 ± 5.5 (1.4) 0.0028 0.0078
to emotional problems  0–20, median 10  0–20, median 0
Scale 7 Vitality 12.1 ± 3.8 (1.0) 8.3 ± 2.4 (0.6) 0.0011 0.0012
median 12  median 8.5
Scale 8 General health 12.7 ± 4.2 (1.0) 9.9 ± 4.0 (1.0) 0.0222 0.0294
perception  median 11.5  median 10.5
Total 79.1 ± 29.7 (7.4) 53.5 ± 25.6 (6.4) 0.0005 0.0003
median 90.5  median 55
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It must be mentioned that AMS is not AF-spe-
cific and may be triggered by other supraventricu-
lar arrhythmias, frequent extra atrial beats or by
atrial oversensing (R potential far-fields). Some of
the AMS episodes might thus be an effect of other
events. The absence of IEGM in the implanted
pacemakers prevented verification and exclusion of
falsely diagnosed AF events.
QoL, which qualifies only as a secondary end-
point in many studies, is a very important effect of
treatment for the majority of patients. In AF pa-
tients the symptom spectrum is usually very broad
and unspecific. A QoL questionnaire was a very
helpful tool in assessing the results of therapy. In
the group presented here QoL as assessed by SF-36
was improved in a way similar to the improvement
demonstrated by the INOVA study [19]. All sub-
scales improved except those describing physical
functioning and bodily pain. In the INOVA study no
statistical difference was achieved in a sub-scale
concerning perception of general health.
The improvement in QoL was probably
achieved as a result of a reduction in AF events,
outpatient visits and hospitalisations, although the
greater stabilisation of ventricular rhythm by DDI
pacing might also have resulted in greater tolerance
of arrhythmia.
Study limitations
The patients were not randomised and the
study population was relatively small.
Pharmacotherapy was at the discretion of the
treating practitioners and in some patients treat-
ment was modified. Because of the number of pa-
tients involved no conclusion can be drawn concern-
ing the influence of drugs on the results.
The AMS is not AF-specific and the AFS algo-
rithm function is not renowned for its optimal anti-
arrhythmic effect [20, 21].
We did not specify a site for right atrium pac-
ing and the sites chosen may have varied accord-
ing to the preference of the operating cardiologist.
Because pacing site may per se be of importance this
cannot be analysed in our study [22–24].
Conclusions
1. Atrial overdrive pacing by preventing one of the
atrial pro-arrhythmic mechanisms reduces the
number of AF events, the AF burden, the
number of hospitalisations and outpatient vis-
its and improves the quality of life.
2. Atrial overdrive pacing is a safe and well tole-
rated feature.
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